Literature DB >> 19545501

Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines.

Jennifer A Johnson1, Paul E Sax.   

Abstract

The improved efficacy and safety of antiretroviral agents have fundamentally changed the face of HIV infection. Advances in antiretroviral therapy have dramatically improved the prognosis of HIV infection, which is now on a par with other chronic illnesses. This article addresses the optimal timing of antiretroviral therapy initiation and the optimal drug choices for initial regimens, with a focus on recent data and published guidelines issued by the US Department of Health and Human Services and the International AIDS Society-USA.

Entities:  

Year:  2009        PMID: 19545501     DOI: 10.1007/s11908-009-0046-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  25 in total

1.  Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Authors:  Wendy P Bannister; Lidia Ruiz; Alessandro Cozzi-Lepri; Amanda Mocroft; Ole Kirk; Schlomo Staszewski; Clive Loveday; Anders Karlsson; Antonella d'Arminio Monforte; Bonaventura Clotet; Jens D Lundgren
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177

2.  A comparison of three initial antiretroviral AIDS regimens.

Authors:  Heather J Ribaudo; Daniel R Kuritzkes; Roy M Gulick
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

3.  Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.

Authors:  Heidi M Crane; Stephen E Van Rompaey; Mari M Kitahata
Journal:  AIDS Patient Care STDS       Date:  2007-12       Impact factor: 5.078

4.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

5.  Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

Authors:  Sharon Walmsley; Anchalee Avihingsanon; Jihad Slim; Douglas J Ward; Kiat Ruxrungtham; Jason Brunetta; U Fritz Bredeek; Dushyantha Jayaweera; Carol Jean Guittari; Peter Larson; Malte Schutz; François Raffi
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

6.  Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Authors:  Yves Benhamou; Herve Fleury; Pascale Trimoulet; Isabelle Pellegrin; Renaud Urbinelli; Christine Katlama; Willy Rozenbaum; Gwenael Le Teuff; Aldo Trylesinski; Christophe Piketty
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

7.  Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.

Authors:  Johan van Griensven; Rony Zachariah; Freya Rasschaert; Edi F Atté; Tony Reid
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-10-02       Impact factor: 2.184

8.  Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.

Authors:  Jean B Nachega; Michael Hislop; David W Dowdy; Joel E Gallant; Richard E Chaisson; Leon Regensberg; Gary Maartens
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

9.  Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Authors:  Jean-François Delfraissy; Philippe Flandre; Constance Delaugerre; Jade Ghosn; Andrzej Horban; Pierre-Marie Girard; Michael Norton; Christine Rouzioux; Anne-Marie Taburet; Isabelle Cohen-Codar; Philippe Ngo Van; Jean-Pierre Chauvin
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177

10.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Authors:  Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Alexandra Thiry; Donnie McGrath
Journal:  Lancet       Date:  2008-08-23       Impact factor: 79.321

View more
  1 in total

1.  Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.

Authors:  Robert C Kauffman; Andradi Villalobos; Joanne H Bowen; Lourdes Adamson; Raymond F Schinazi
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.